It’s no secret that so-called PARP inhibitors, a new class of cancer drugs, have struggled to gain traction commercially, even as they’ve shown promise treating multiple tumor types. But today brings news that could bolster the future prospect of PARP blockers: one of them, a drug known as olaparib (Lynparza) from AstraZeneca and partner Merck, may work treating pancreatic cancer, a particularly fast-moving, deadly tumor with limited treatment options.
AstraZeneca (NYSE: AZN) and Merck (NYSE: MRK) said today that olaparib has met its main goal in a Phase 3 study in 154 pancreatic cancer patients whose tumors have… Read more »
